Black Diamond Financial LLC Acquires 661 Shares of Eli Lilly and Company (NYSE:LLY)

Black Diamond Financial LLC raised its position in shares of Eli Lilly and Company (NYSE:LLY) by 42.7% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 2,210 shares of the company’s stock after purchasing an additional 661 shares during the quarter. Black Diamond Financial LLC’s holdings in Eli Lilly and Company were worth $1,706,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in the company. BCGM Wealth Management LLC grew its stake in shares of Eli Lilly and Company by 14.2% during the 4th quarter. BCGM Wealth Management LLC now owns 4,700 shares of the company’s stock valued at $3,628,000 after purchasing an additional 585 shares during the period. World Equity Group Inc. grew its stake in shares of Eli Lilly and Company by 6.7% during the 4th quarter. World Equity Group Inc. now owns 807 shares of the company’s stock valued at $623,000 after purchasing an additional 51 shares during the period. Delta Financial Group Inc. bought a new stake in shares of Eli Lilly and Company during the 4th quarter valued at about $5,196,000. Ascent Wealth Partners LLC lifted its position in shares of Eli Lilly and Company by 3.1% during the 4th quarter. Ascent Wealth Partners LLC now owns 4,009 shares of the company’s stock valued at $3,095,000 after buying an additional 119 shares in the last quarter. Finally, Cabot Wealth Management Inc. lifted its position in shares of Eli Lilly and Company by 1.7% during the 4th quarter. Cabot Wealth Management Inc. now owns 6,355 shares of the company’s stock valued at $4,906,000 after buying an additional 107 shares in the last quarter. 82.53% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of research analysts have recently weighed in on the company. StockNews.com raised Eli Lilly and Company from a “hold” rating to a “buy” rating in a research report on Friday, February 7th. Leerink Partners set a $950.00 price objective on Eli Lilly and Company in a research report on Friday, January 17th. Bank of America reaffirmed a “buy” rating and set a $997.00 price objective on shares of Eli Lilly and Company in a research report on Tuesday, December 10th. Wolfe Research assumed coverage on Eli Lilly and Company in a research report on Friday, November 15th. They set an “outperform” rating and a $1,000.00 price objective on the stock. Finally, Wells Fargo & Company lowered their price objective on Eli Lilly and Company from $1,000.00 to $970.00 and set an “overweight” rating on the stock in a research report on Tuesday, January 28th. Three investment analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $1,000.28.

Eli Lilly and Company Stock Up 0.1 %

Shares of LLY opened at $874.12 on Monday. The stock has a market capitalization of $828.82 billion, a price-to-earnings ratio of 74.65, a price-to-earnings-growth ratio of 1.40 and a beta of 0.42. Eli Lilly and Company has a 1 year low of $711.40 and a 1 year high of $972.53. The business’s 50 day simple moving average is $801.33 and its 200-day simple moving average is $847.66. The company has a debt-to-equity ratio of 2.00, a current ratio of 1.15 and a quick ratio of 0.97.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Thursday, February 6th. The company reported $5.32 earnings per share for the quarter, missing the consensus estimate of $5.45 by ($0.13). Eli Lilly and Company had a net margin of 23.51% and a return on equity of 85.24%. As a group, equities analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, March 10th. Stockholders of record on Friday, February 14th will be given a dividend of $1.50 per share. The ex-dividend date of this dividend is Friday, February 14th. This represents a $6.00 annualized dividend and a dividend yield of 0.69%. This is an increase from Eli Lilly and Company’s previous quarterly dividend of $1.30. Eli Lilly and Company’s payout ratio is currently 51.24%.

Eli Lilly and Company declared that its board has authorized a stock buyback plan on Monday, December 9th that authorizes the company to buyback $15.00 billion in outstanding shares. This buyback authorization authorizes the company to reacquire up to 2% of its shares through open market purchases. Shares buyback plans are often an indication that the company’s board believes its stock is undervalued.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.